Get started by downloading the provider guide or explore ordering options to bring MyRisk to your practice.
Download provider overview
Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on MyRisk and your testing options.
Download patient guide
MyRisk evaluates 48 clinically actionable genes to provide a comprehensive, guideline-driven assessment across 11 common cancer sites, empowering healthcare providers to personalize care plans.
MyRisk provides you with more critical answers for more patients by definitively classifying up to 63% of variants that other labs could not.1
Did you know that up to 10% of germline variants are missed by tumor testing alone?2 MyRisk identifies germline BRCA1/2 variants that may impact use of targeted therapies such as PARP inhibitors.3,4
MyRisk identifies hereditary cancer syndromes associated with a risk for secondary cancers, directly impacting treatment decisions to reduce the occurrence of subsequent cancer.
National Guidelines recommend germline testing as part of the workup for patients diagnosed with ovarian, breast, pancreatic, prostate, and colon cancer.6 Additionally, while genomic testing has long been recommended for all patients diagnosed with metastatic or advanced cancers, the American Society of Clinical Oncology (ASCO) now advises multigene germline testing for patients who meet criteria regardless of their tumor results.2
MyRisk germline testing is appropriate for patients diagnosed with:
*eligible for MyRisk STAT†
MyRisk germline testing assesses 48 genes linked to one or more of 11 cancer sites.
Every MyRisk test report includes:
A mutation has been identified.
An elevated risk has been identified.
No clinically significant mutation.
Mutation of uncertain risk has been identified.
Myriad is the industry leader in variant classification and reclassification. We use proprietary variant classification tools, including RNA testing and other cutting-edge technology, to provide comprehensive, clinically actionable and iaccurate results.
MyRisk offers the industry’s lowest reported rates of BRCA1/2 VUS of <1.0%1,3
Our Lifetime Classification Commitment sends amended reports whenever a patient’s MyRisk VUS result is reclassified as clinically significant
MyRisk definitively classifies up to 63% of variants other labs could not5
Myriad pioneered the use of RNA analysis in 2015 and offers RNA analysis to all patients with an eligible VUS, giving providers and patients access to this valuable tool at no additional cost.
There should not be a trade-off between turnaround time and receiving an accurate, comprehensive risk assessment when determining surgical treatment for patients. MyRisk STAT was developed for trusted results without the wait.
MyRisk STAT test results for Breast and Pancreatic cancer patients†
Results delivered for all other patients
Provider completes the test request form (in the portal or via paper TRF)
Patient blood or saliva sample is collected and submitted to Myriad Genetics with the test kit
Results are sent to the ordering provider (in the portal or via mail)
With Myriad Oncology, you can receive comprehensive results for germline and tumor genomic testing in one single ordering experience, getting clear, fast answers for your patients.
For a complete approach to cancer risk management and treatment planning, MyRisk germline should be combined with tumor genomic testing to deliver powerful results informing patient care across the entire journey-from assessing hereditary cancer syndromes to guiding treatment decisions.
For your patients with advanced cancer, combine germline and tumor genomic insights to identify hereditary cancer risks and actionable mutations, enabling personalized treatment plans and targeted therapies. MyRisk and Precise Tumor focus on clinically relevant variations in the genome, where each test couples RNA analysis with DNA sequencing to provide more refined interpretation of results.
For your patients with early-stage breast cancer, pair germline testing with tumor genomic insights and breast cancer recurrence assessment to guide personalized decisions on risk-reducing surgeries and adjuvant therapy strategies.
For your patients with ovarian cancer at any stage, integrate germline and tumor genomic insights with tumor homologous recombination deficiency (HRD) testing to inform comprehensive treatment options with PARP inhibitors.
Every MyRisk test delivers treatment-focused reporting with actionable summaries, providing clear guidance for surgical and treatment decisions to support more confident patient care.
MyRisk delivers unmatched accuracy, with variant classification techniques independently verified and clinically validated at >99.9% accuracy.3
Transparent pricing with personalized cost estimates, financial assistance, and other affordability options including direct pay.
NCCN = National Comprehensive Cancer Network® (NCCN®)
†Patients with government payers (Medicare, Medicare Advantage, TriCare) are not eligible for MyRisk STAT.
Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.